Miriam Koopman.

Jolien Tol, M tadacip .D., Miriam Koopman, M.D., Annemieke Cats, M.D., Ph.D., Cees J. Rodenburg, M.D., Ph.D., Geert J.M. Creemers, M.D., Ph.D., Jolanda G. Schrama, M.D., Frans L.G. Erdkamp, M.D., Ph.D., Allert H. Vos, M.D., Cees J. Van Groeningen, M.D., Ph.D., Damage A.M. Sinnige, M.D., Ph.D., Dirk J. Richel, M.D., Ph.D., Emile E. Voest, M.D., Ph.D., Jeroen R. Dijkstra, B.Sc., Marianne E.Sc., Ninja F. Antonini, M.Sc., Linda Mol, M.Sc., Johan H.J.M. Van Krieken, M.D., Ph.D., Otilia Dalesio, M.Sc., and Cornelis J.A. Punt, M.D., Ph.D.: Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer Fluoropyrimidines , irinotecan, and oxaliplatin will be the standard cytotoxic drugs used in treating metastatic colorectal cancer.1,2 The mix of capecitabine and oxaliplatin is similar to the mix of fluorouracil and oxaliplatin in efficacy and safety.3,4 Bevacizumab, a humanized monoclonal antibody against vascular endothelial development factor , 5-7 coupled with fluoropyrimidine-based chemotherapy is currently the standard first-range treatment for metastatic colorectal cancer tumor.

The FOLFIRI group experienced a median duration of 25.7 weeks of irinotecan treatment and 25.7 weeks of fluorouracil treatment. The median duration of follow-up was 29.9 months with cetuximab plus FOLFIRI and 29.4 months with FOLFIRI alone. In the primary analysis population, post-study chemotherapy with or without EGFR antibody therapy was administered to 63.9 percent and 6.2 percent of individuals, respectively, receiving FOLFIRI plus cetuximab and 68.8 percent and 25.4 percent, respectively, of those receiving FOLFIRI. The findings were equivalent for the KRAS people.